Skip to main content

Table 3 Comparisons of clinical parameters between CLD-C patients seropositive and seronegative for ANAs

From: Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease

 

ANA-positive (n = 9)

ANA-positive (n = 13)

p value

Age (y.o.)

62.2 ± 5.9

56.9 ± 7.7

0.0883

Gender (male/female)

3/6

7/6

0.4149

BMI

24.5 ± 4.4

23.3 ± 3.1

0.4905

HOMA-IR value

3.01 ± 1.31

1.28 ± 0.50

0.0011

ALT (IU/L)

129 ± 90

38 ± 22

0.0024

IgG (mg/dL)

2282 ± 336

1467 ± 244

0.0008

Ferritin (ng/ml)

450 ± 405

141 ± 87

0.0056

Hepatic fibrosis (F0/F1/F2/F3/F4)

0/5/2/2

9/3/1/0

0.0014

Hepatic steatosis (grade 0/1/2)

2/3/4

6/7/0

0.0430

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us